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Abstract
Background: Patients asking for a free anonymous HIV test may have contracted other sexually transmitted
infections (STIs) such as Chlamydia trachomatis, yet Chlamydia prevalence in that population is unknown. This study
aimed to assess the prevalence and factors associated with Chlamydia infection in patients seeking HIV testing at
local public health authorities (LPHA) in order to evaluate whether Chlamydia testing should be routinely offered to
them.
Methods: We conducted a cross-sectional study among patients (≥18 years) attending 18 LPHA in North Rhine-
Westphalia from November 2012 to September 2013. LPHA collected information on participants’ socio-
demographic characteristics, sexual and HIV testing behaviours, previous STI history and clinical symptoms. Self-
collected vaginal swabs and urine (men) were analysed by Transcription-Mediated Amplification. We assessed
overall and age-stratified Chlamydia prevalence and 95 % confidence intervals (95 % CI). Using univariate and
multivariable binomial regression, we estimated adjusted prevalence ratios (aPR) to identify factors associated with
Chlamydia infection.
Results: The study population comprised 1144 (40.5 %) women, 1134 (40.1 %) heterosexual men and 549 (19.4 %)
men who have sex with men (MSM); median age was 30 years. Chlamydia prevalence was 5.3 % (95 % CI: 4.1–6.8 %)
among women, 3.2 % (95 % CI: 2.2–4.4) in heterosexual men and 3.5 % (95 % CI: 2.1–5.4) in MSM. Prevalence was
highest among 18–24 year-old women (9 %; 95 % CI: 5.8–13) and heterosexual men (5.7 %; 95 % CI: 3.0–9.8 %),
respectively. Among MSM, the prevalence was highest among 30–39 year-olds (4.4 %; 95 % CI: 1.9–8.5 %). Among
those who tested positive, 76.7 % of women, 75.0 % of heterosexual men and 84.2 % of MSM were asymptomatic.
Among women, factors associated with Chlamydia infection were young age (18–24 years versus ≥ 40 years,
aPR: 3.0, 95 % CI: 1.2–7.8), having had more than 2 partners over the past 6 months (ref.: one partner, aPR:
2.1, 95 % CI: 1.1–4.0) and being born abroad (aPR: 1.9, 95 % CI: 1.0–3.5). Among heterosexual men, young age
was associated with Chlamydia infection (18–24 years versus≥ 40 years, aPR: 4.1, 95 % CI: 1.3–13). Among MSM, none
of the variables were associated with Chlamydia infection.
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Conclusions: LPHA offering HIV tests should consider offering routine Chlamydia testing to women under 30 years.
Women with multiple partners and those born abroad may also be considered for routine testing. Our results also
suggest offering routine Chlamydia testing to heterosexual men under 25 years old. For MSM, we cannot draw specific
recommendations based on our study as we estimated the prevalence of urethral Chlamydia infection, leaving out
rectal and pharyngeal infections.
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Background
Chlamydia trachomatis (hereafter referred to as Chla-
mydia) is the most common bacterial STI in Europe [1].
In 2012, the rate of diagnosed Chlamydia cases reported
to ECDC by 26 EU/EEA member states was 184 per 100
000 population (385 307 cases) [1]. Untreated, Chla-
mydia can cause serious sequelae among women, includ-
ing pelvic inflammatory disease which can result in
infertility, ectopic pregnancy and chronic pelvic pain. In
men, untreated Chlamydia infection can lead to acute
genital inflammation (epididymitis, epididymo-orchitis)
and occasionally to sexually-acquired reactive arthritis
(SARA) [2]. Chlamydia infection can facilitate the trans-
mission of HIV [3] and is often asymptomatic for be-
tween 70 and 90 % of women, and over 50 % of men [4].
Asymptomatic carriers may remain undetected and rep-
resent a major reservoir for Chlamydia spread.
There are currently few data on the prevalence of
Chlamydia in Germany as reporting of this STI is not
mandatory. In a German population-based survey con-
ducted among adolescents (2003–2006), the prevalence
of Chlamydia infection was 2.2 % (95 % CI: 1.4–3.5) in
girls aged 15–17 years and 0.2 % (95 % CI: 0.1–0.7) in
boys aged 16–17 years [5].
In Germany, Chlamydia screening is recommended
and free of charge for women under 25 years old (annu-
ally), pregnant women and women planning an abortion;
there is no recommendation to screen asymptomatic
men. Results from the German national surveillance net-
work of laboratories showed that the proportion of posi-
tive tests was 3.9 % (139,632/3,540,860) among women
(2008–2014). The proportion of positive tests was
11.9 % (27,720/233,692) among men [6], however physi-
cians tend to offer Chlamydia testing mostly to symp-
tomatic men since tests for men are only reimbursed by
the statutory health system when they are symptomatic.
Therefore, the proportion of positive Chlamydia tests
among asymptomatic men and the prevalence among
men regardless of symptom onset cannot be drawn from
the German surveillance data.
Local public health authorities (LPHA) offer free an-
onymous HIV testing and counselling. Patients asking
for an HIV test at a LPHA may have contracted other
STIs such as Chlamydia. Compared to the general
population, Chlamydia prevalence may be higher among
persons seeking HIV testing at LPHA, since having un-
protected sex is the second most frequent reason to ask
for an HIV test, the first reason being having a new part-
ner [7]. Chlamydia tests are not routinely offered to per-
sons attending LPHA for an HIV test: in a survey
conducted in 2012 among 250 LPHA offering STI/HIV
counselling and testing, just 27 % offered Chlamydia
testing [8]. Thus, Chlamydia tests are not routinely of-
fered to persons attending LPHA for an HIV test. In
2012, the STI-HIT cross-sectional study commenced,
with participating LPHA in North Rhine-Westphalia of-
fering screening for Chlamydia and Gonorrhoea to pa-
tients seeking HIV testing. The focus of this article is on
Chlamydia. We assessed the prevalence and factors asso-
ciated with Chlamydia infection in patients seeking HIV
testing at local public health authorities in order to evalu-
ate whether Chlamydia testing should be routinely offered
to them.
Methods
Setting and study population
In Germany, responsibility for public health is decentra-
lised, with most public health activities being financed by
rural or urban district authorities. LPHA are in charge of
providing public health services at the county level. Ser-
vices they offer range from vaccination, pediatric care,
mental health, social medicine, hygiene and environmental
health, to health promotion. According to the Infection
Protection Act, LPHA should provide anonymous STI/
HIV counseling and testing. The range of STI tests offered
varies highly across LPHA [8].
The initial sampling design was a simple cluster sample.
Each participating LPHA represented a cluster. Within a
cluster, the variance in Chlamydia prevalence between
participants was expected to be less than the variance in
Chlamydia prevalence between clusters. This was taken
into account in the calculation of the sample size with a
so-called “design effect” of 2. Assuming a prevalence of
1 % (gonorrhea) up to 12 % (Chlamydia) and a power of
80 %, about 979 participants were expected to be included
in the study (precision ranging from 1 to 3 %). This num-
ber was multiplied by 2 to take into account the design ef-
fect due to cluster sampling. Assuming a response
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proportion of 70 %, up to 2545 participants were initially
expected to be included in the study.
There are 53 LPHA offering HIV testing in North-
Rhine-Westphalia, the largest federal state located in the
western part of Germany (~17.5 million inhabitants). All
LPHA were offered to take part in the study. Between
November 2012 and September 2013, 18 LPHA agreed
to participate in the study and offered Chlamydia testing
anonymously and free of charge to patients seeking HIV
testing. All eligible patients attending LPHA were invited
to participate. LPHA staff recruited study participants
and offered a Chlamydia test to all of them. Chlamydia
testing was independent of whether the patient actually
took an HIV test. All patients 18 years old or more were
eligible to participate in the study. Persons who met the
exclusion criteria for participation in the study were
pregnant, breast-feeding or menstruating women and
persons who are already enrolled in the study. Because
pregnant women are a special population requiring spe-
cific precautions, the ethical committee has imple-
mented strict procedures for their inclusion in clinical
studies and we decided not to include them in this
study. To be noted that women in Germany are system-
atically offered free Chlamydia testing during their preg-
nancy. As transgenders were few and because the vast
majority of sex workers were recruited by one single
LPHA, we decided to exclude them from this analysis in




After giving oral informed consent, study participants
were administered by LPHA staff a short paper-based
questionnaire providing information on their socio-
demographic characteristics, sexual and HIV testing be-
haviours, previous STI history and clinical symptoms.
Diagnostic tests
Specimens were obtained through self-collected vaginal
swabs and urine (men). All samples were collected at
LPHA. These specimens were analysed by Transcription-
Mediated Amplification (APTIMA Combo2®), a nucleic
acid amplification technique targeting ribosomal RNA.
Statistical analysis
Data analyses were performed using Stata, V.13. For
categorical variables, we calculated frequencies and pro-
portions. Chi squared tests were used when proportions
were compared to detect possible differences between
groups. For continuous variables, we calculated the me-
dian and presented the 1st and 3rd quartiles [Q1-Q3].
Due to different risk profiles in the study population, we
stratified this analysis by three sub-populations: women,
heterosexual men and MSM. We assessed overall and
age-stratified Chlamydia prevalence and 95 % confidence
intervals (CI). Using univariate and multivariable bino-
mial regression, we estimated adjusted prevalence ratios
(aPR) and 95 % CI to identify factors associated with
Chlamydia infection. All variables with P < 0.25 in the
univariate analysis were included in the multivariable
model; we excluded the variables when less than 10
participants presented the outcome of interest. Overall
significance was set at P < 0.05 in the multivariable
model. We built a separate model for each group. For
heterosexual men, the variable ‘number of partners’ was
forced into the multivariable model as we expected it to
be a key factor influencing the outcome. Similarly, for
MSM, we forced ‘age group’ and ‘number of partners’ in
the multivariable model. Since our study included 18
LPHA from cities in North-Rhine-Westphalia, we tried
to use a mixed model to adjust for heterogeneity be-
tween the LPHA. However, this model did not signifi-
cantly improve the model fit.
Data protection and privacy
Ethical approval was obtained from Charite - University
Medicine Berlin (approval number EA1/142/12). Data
collected through the questionnaire as well as the la-
boratory results were anonymised. A unique barcode
was assigned to each patient and used to link laboratory
results with the corresponding questionnaire. This bar
code allowed health care counsellors to get back to
the patient with the test result, and to plan further
appointments for counselling and treatment when ne-
cessary. After the questionnaire and laboratory data
had been linked, the barcode was removed from the
dataset so that the Robert Koch Institute received an
anonymised dataset.
Results
Sociodemographic, behavioral and clinical characteristics
of study participants
A total of 3204 study participants enrolled in the STI-HIT
study and 2827 were included in this analysis (Fig. 1).
The population under study consisted of 40.5 % of
women, 40.1 % of heterosexual men and 19.4 % of MSM.
The median age was 30 years [Q1-Q3: 25–38]. Seventy-
three percent completed a high-school diploma (“Abitur/
Fachabitur”, 12 to 13 years of schooling) and 18 % com-
pleted a secondary-school diploma (“Realschule”, 10 years
of schooling). The main reasons for getting an HIV test
were having sexual contact with a person of unknown
HIV status (64.1 %) and having a new partner (34.3 %).
The proportion of participants having an HIV test for the
first time was twice higher in women (61.5 %) and hetero-
sexual men (60.8 %) compared to MSM (29.9 %). The me-
dian number of partners over the past 6 months was
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highest among MSM (3 [Q1-Q3:2–6]), followed by het-
erosexual men (2 [Q1-Q3:1–3]) and women (1 [Q1-Q3:1–
2]). Overall, 15.4 % of study participants had symptoms at
the time of counselling. Additional characteristics are
summarised in Table 1.
Prevalence of Chlamydia infection
The overall prevalence of Chlamydia infection was 5.3 %
(61/1144; 95 % CI: 4.1 – 6.8 %) among women, 3.2 %
(36/1134; 95 % CI: 2.2 – 4.4) in heterosexual men and
3.5 % (19/549; 95 % CI: 2.1–5.4) in MSM. In women, the
prevalence was highest in the younger age groups,
reaching 9.0 % (95 % CI: 5.8–13) among the 18–24 year-
olds - the prevalence in this group differed significantly
from the prevalence in the two older age groups (Fig. 2).
The same pattern can be observed among heterosexual
men - the highest prevalence was also found among the
18–24 year-olds (5.7 %; 95 % CI: 3.0–9.8 %) - but the
higher prevalence in the younger age groups was not
statistically significant when compared to the two other
age groups. As to MSM, the overall pattern was different
with the highest prevalence found among the 30–39
year-olds (4.4 %; 95 % CI: 1.9–8.5 %), followed by the
18–24 year-olds; the confidence intervals widely over-
lapped across all age groups (Fig. 2).
Prevalence of asymptomatic infections
Among Chlamydia positive women, 76.7 % were asymp-
tomatic. Among Chlamydia positive men, 75.0 % of the
heterosexual men and 84.2 % of the MSM were asymptom-
atic. There was no significant difference between all three
groups (P = 0.726).
Factors associated with Chlamydia infection
Univariate binomial regression
Among women, age group, number of partners and vagi-
nal discharge were associated with Chlamydia infection
in the univariate analysis. However, only nine Chlamydia
positive women reported discharge symptoms. Among
heterosexual men, only age group was associated with
Chlamydia infection in the univariate analysis. Among
MSM, only penile discharge and painful urination were
associated with Chlamydia infection in the univariate
analysis. However, the absolute numbers were small
among MSM who reported penile discharge (n = 1) or
painful urination (n = 2). Therefore, these two variables
were not included in the multivariable model.
Multivariable binomial regression
Among women, factors associated with Chlamydia infec-
tion in the multivariable model were young age (18–24
years versus ≥ 40 years of age, aPR: 3.0, 95 % CI: 1.2–
7.8), having had more than two partners over the past
6 months (ref.: one partner, aPR: 2.1, 95 % CI 1.1–4.0)
and being born abroad (aPR: 1.9, 95 % CI: 1.0–3.5).
None of the other factors was associated with testing
positive for Chlamydia in the final model (Table 2).
Fig. 1 Flow chart of study participants
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Among heterosexual men, young age was the only fac-
tor associated with Chlamydia infection in the multivari-
able model (18–24 years versus ≥ 40 years of age, aPR:
4.1, 95 % CI: 1.3–13) (Table 2). Among MSM, age was
not found to be associated with Chlamydia infection
(18–24 years versus ≥ 40 years of age, aPR: 1.7, 95 % CI:
0.4–6.6), nor was number of partners (ref.: one partner,
aPR: 2.8, 95 % CI 0.6–12) (Table 2).
Discussion
In our study, the prevalence of Chlamydia infection was
high among women under 30 years-old and heterosexual
men under 25 years (point estimate above 5 %). Chla-
mydia prevalence was also above 4 % among the 25–29
year-olds in heterosexual men, and among the 30–39
year-olds in MSM. Looking at point estimates, the over-
all pattern was similar among women and heterosexual
Table 1 Sociodemographic, behavioral and clinical characteristics of study participants (N = 2827)
Women (N = 1144) Heterosexual men (N = 1134) MSM (N = 549)
Median age [Q1-Q3]: 29 [25–35] 31 [26–39] 32 [26–41]
n (%) n (%) n (%)
Level of education:
Did not finish school 13 (1.3) 12 (1.1) 3 (0.6)
Still in school 6 (0.6) 6 (0.6) 2 (0.4)
Secondary school education (Hauptschuleabschluss) 66 (6.4) 91 (8.8) 44 (8.6)
Secondary school diploma (Realschuleabschluss) 171 (16.5) 200 (19.2) 85 (16.5)
High-school diploma (Abitur/Fachabitur) 782 (75.3) 732 (70.3) 380 (74.0)
Missing values 106 93 35
Born in Germany: 938 (83.5) 878 (79.4) 449 (83.3)
Missing values: 20 28 10
Having an HIV test for the first time (yes): 703 (61.5) 689 (60.8) 164 (29.9)
Missing values 15 12 1
Reason for getting tested (multiple answers possible):
Intercourse with a person of unknown HIV status 699 (63.3) 668 (60.4) 394 (73.0)
New partner 408 (37.1) 418 (37.8) 115 (21.3)
Intercourse with known HIV + person 13 (1.2) 10 (0.9) 51 (9.4)
Intercourse with sex workers 0 116 (10.5) 9 (1.7)
Injectable drug user 2 (0.2) 3 (0.3) 0 (0.0)
Occupational exposure 25 (2.3) 9 (0.8) 5 (0.9)
Other reason 85 (7.7) 66 (6.0) 55 (10.2)
Missing values 43 29 9
Number of partners over the past 6 months:
0 53 (5.9) 20 (1.8) 4 (0.9)
1 428 (47.6) 297 (26.2) 101 (23.4)
2 238 (26.4) 255 (22.5) 69 (16.0)
≥ 3 183 (20.3) 321 (28.3) 257 (59.6)
Missing values 242 241 118
Currently has a stable partner: 620 (56.6) 692 (63.3) 257 (48.2)
Missing values 48 41 16
Previous STI history:
Yes 156 (14.2) 138 (12.9) 145 (27.6)
Do not know 19 (1.7) 40 (3.6) 19 (3.5)
Missing values 25 12 5
Symptoms at time of counselling (yes): 228 (20.4) 137 (12.3) 62 (11.5)
Missing values 28 16 10
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men - a decrease in the prevalence was observed as age
increased - and differed with that of MSM for whom age
did not seem to be a key factor associated with urethral
Chlamydia infection. This was confirmed in the multi-
variable analysis: the prevalence of Chlamydia infection
was significantly higher among women and heterosexual
men aged 18 to 24 years whereas age group was not as-
sociated with Chlamydia infection among MSM in the
univariate and multivariable analysis. Across all three
groups, the vast majority of participants who tested posi-
tive for Chlamydia were asymptomatic. As previously
highlighted, only testing of symptomatic men is reim-
bursed by the German statutory health system. Since
Chlamydia infection is often asymptomatic in men as
well, the vast majority of positive tests is missed when
testing symptomatic men only, fueling the reservoir of
asymptomatic carriers. In this study, above three quar-
ters of Chlamydia infection would have been missed
among men if only symptomatic men had been tested.
This raises the question as to Chlamydia screening not
only among asymptomatic women but also among
asymptomatic men.
The presently scarce data on Chlamydia prevalence in
Germany include two cross-sectional studies: one was
conducted among adolescents in the general population
[5], the other one was conducted among MSM attending
local health offices, STI clinics and private medical prac-
tices in Germany [9]. In the German context, we were
only able to compare our results for specific age groups
with the proportion of positive tests based on data from
the surveillance network of laboratories in North Rhine-
Westphalia. However, these surveillance data cannot be
interpreted as a measure of Chlamydia prevalence as the
proportion of positive tests is highly dependent on
screening recommendations.
Our study provides data as to Chlamydia prevalence
among persons attending LPHA for an HIV test, which
was previously unknown. Prevalence of Chlamydia infec-
tion was assessed in three sub-populations (women, hetero-
sexual men and MSM) in order to distinguish specific
recommendations for each group.
Chlamydia screening in Germany is recommended and
reimbursed by the statutory health system for women
under 25 years old. Our results showed that Chlamydia
prevalence reached 9.0 % among 18–24 year-old women
seeking HIV testing at a LPHA. In comparison, the pro-
portion of positive Chlamydia tests in that same age group
was 4.8 % based on data from the national surveillance
network of laboratories for North Rhine-Westphalia [6].
Similarly, the overall Chlamydia prevalence estimated
among women (5.3 %) was also higher compared to data
from the national surveillance network of laboratories for
North Rhine-Westphalia (proportion of positive tests:
3.8 % [3.7–3.8 %], 2008–2014).
For men, the prevalence estimated in this study can
hardly be compared with the proportion of positive tests
from the surveillance data as tests for men are only re-
imbursable when they are symptomatic. In the case of
men, the German surveillance data are likely to overesti-
mate Chlamydia prevalence since only symptomatic men
tend to be tested.
In this study, men were tested for Chlamydia using
urine samples. Therefore, we could only estimate the
prevalence of urethral Chlamydia infection. In a cross-
Fig. 2 Prevalence of Chlamydia trachomatis infection by age group in women, heterosexual men and MSM. For each bar, the back line represents
the 95 % confidence interval
Lallemand et al. BMC Infectious Diseases  (2016) 16:610 Page 6 of 10
Table 2 Associations between variables and Chlamydia trachomatis infection in women, heterosexual men and MSM
Variables Crude prevalence of
Chlamydia infection %
(n/N) Unadjusted PR (95 % CI) P value Adjusted PR (95 % CI)
Women (N = 1144) Number of participants in the final model: N = 839
Age group (years)
≥ 40 (ref.) 2.5 (5/202) Ref. Ref.
18–24 9.0 (25/279) 3.6 (1.4–9.3) 0.007 3.0 (1.2–7.8)
25–29 6.8 (22/345) 2.6 (1.0–6.7) 0.052 1.9 (0.7–4.8)
30–39 2.8 (9/318) 1.1 (0.4–3.4) 0.808 1.0 (0.3–2.9)
No. of partners
1 (ref.) 4.4 (19/428) Ref. Ref.
0 0 (0/53) - -
2 6.7 (16/238) 1.5 (0.8–2.9) 0.208 1.4 (0.8–2.7)
≥ 3 9.3 (17/183) 2.1 (1.1–3.9) 0.022 2.1 (1.1–4.0)
Country of birth (ref. = Germany) 5.0 (47/938) Ref.
Abroad 7.5 (14/186) 1.5 (0.8–2.7) 0.166 1.9 (1.0–3.5)
Vaginal discharge (ref. = no) 4.9 (52/1073) Ref.
Yes 12.7 (9/71) 2.6 (1.3–5.1) 0.005 - -
Reason for getting tested
(ref. = not a reason for getting tested) 4.2 (17/404) Ref.
Intercourse with a person of unknown
HIV status
6.2 (43/697) 1.5 (0.9–.2.6) 0.126 - -
(ref. = not a reason for getting tested) 5.3 (57/1076) Ref.
Occupational exposure 12 (3/25) 2.3 (0.8–6.9) 0.131 - -
Heterosexual men (N = 1134) Number of participants in the final model: N = 854
Age group (years)
≥ 40 (ref.) 1.8 (5/274) Ref. Ref.
18–24 5.7 (12/210) 3.1 (1.1–8.8) 0.029 4.1 (1.3–13)
25–29 4.2 (12/288) 2.3 (0.8–6.4) 0.116 2.0 (0.6–6.7)
30–39 1.9 (7/362) 1.1 (0.3–3.3) 0.920 1.2 (0.3–4.2)
No. of partners
1 (ref.) 3.4 (10/297) Ref. Ref.
0 0.0 (0/20) - -
2 3.5 (9/255) 1.0 (0.4–2.5) 0.917 1.1 (0.4–2.7)
≥ 3 3.4 (11/321) 1.0 (0.4–2.4) 0.967 0.9 (0.4–2.2)
Reason for getting tested
(ref. = not a reason for getting tested) 2.3 (10/437) Ref. Ref.
Intercourse with a person of unknown
HIV status
3.6 (24/668) 1.6 (0.8–3.3) 0.224 1.7 (0.7–3.9)
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sectional study conducted among MSM in Germany [9],
prevalence of urethral Chlamydia was 3.4 % (95 % CI:
2.0–4.7 %) which is consistent with our results. In that same
study, Chlamydia prevalence was 1.5 % (95 % CI: 1.0–2.0 %)
in pharyngeal swabs and 8.0 % (95 % CI: 6.8–9.2 %) in rectal
specimen. Seventy-five percent of Chlamydia infections
were exclusively rectal, supporting other evidence that only
a minority of prevalent infection would be detected when
testing MSM for urethral infections alone [9–11]. Besides,
rectal and pharyngeal infections are often asymptomatic
[12]. The study conducted in Germany highlighted the need
for pharyngeal and rectal Chlamydia testing for MSM, in
addition to screening for urethral infection [9].
There is currently no recommendation to screen asymp-
tomatic men in Germany. In France, systematic Chla-
mydia screening of all men under 30 attending free and
anonymous screening centers, information, diagnosis and
screening centers for sexually transmitted infections, or
family planning and education centers, was recommended
by the National Agency for Health Accreditation and
Evaluation (ANAES) in 2003 [13]. In the United Kingdom,
in primary care, opportunistic screening is recommended
for those in whom the prevalence is known to be the high-
est: the under 25 years old (women and men), those with
more than two partners over the past 12 months or with a
recent change of sexual partner [4].
Cost-effectiveness studies can help inform policy
makers with respect to possible Chlamydia screening
strategies. However, there are challenges in assessing the
cost-effectiveness of Chlamydia screening. In a review of
published cost-effectiveness studies focusing on asymp-
tomatic women under 30 years old in a primary care
setting, a threshold of 3 % was identified as the preva-
lence from which routine screening for Chlamydia is
cost-effective [14]. However, this threshold is questioned
as the probability of developing pelvic inflammatory
disease is yet to be precisely established. The natural his-
tory of untreated Chlamydia cannot be directly observed
in humans for ethical reasons. In 2012, a mathematical
modeling study simulating results of published rando-
mised trials estimated that 10 % (95 % CI: 7–13 %) of
chlamydia infections progress to pelvic inflammatory
disease over one year, assuming constant progression
of the infection to the disease or progression at the
end [15]. Further research is needed in order to as-
sess the cost-effectiveness of screening asymptomatic
men for Chlamydia and to decide which subgroups
among men may be included as part of a wider Chla-
mydia screening strategy.
The results reported here have a number of limita-
tions. We do not have information on the response pro-
portion, therefore we do not know whether those who
did not take part in the study differed from those who
did with respect to Chlamydia infection: selection bias
cannot be ruled out. Most of the local public health au-
thorities who took part in this study were located in
large cities of North Rhine-Westphalia and are more
likely to be representative of LPHA in large cities. Few
rural LPHA participated as they had few clients. The re-
sults reported apply to the federal state of North Rhine-
Westphalia and cannot be extrapolated to the whole of
Germany. In this study, information on condom use was
not collected. It is possibly a key factor associated with
Chlamydia infection as consistent condom use has
shown to be effective in reducing the risk of STI such as
Chlamydia [16]. Information on alcohol and drug con-
sumption were not collected and may also be factors
influencing the outcome [5, 17]. For variables with more
Table 2 Associations between variables and Chlamydia trachomatis infection in women, heterosexual men and MSM (Continued)
MSM (N = 549) Number of participants in the final model: N = 358
Age group (years)
≥ 40 (ref.) 2.7 (4/150) Ref. Ref.
18–24 3.7 (4/108) 1.4 (0.4–5.4) 0.637 1.7 (0.4–6.6)
25–29 2.8 (3/109) 1.0 (0.2–4.5) 0.967 0.4 (0.04–3.4)
30–39 4.4 (8/182) 1.6 (0.5–5.3) 0.412 1.3 (0.4–4.3)
No. of partners
1 (ref.) 2.0 (2/101) Ref. Ref.
0 0.0 (0/4) - -
2 0.0 (0/69) - -
≥ 3 5.1 (15/431) 2.6 (0.6–11) 0.211 2.8 (0.6–12)
Penile discharge (ref. = no) 3.3 (18/546) Ref.
Yes 33.3 (1/3) 10.1 (1.9–53) 0.006 - -
Painful urination (ref. = no) 3.2 (17/534) Ref.
Yes 13.3 (2/15) 4.2 (1.1–17) 0.041 - -
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than 10 % of missing values, multiple imputation of the
missing data is an option if the data are missing at ran-
dom. In our study, the proportion of missing values for
‘number of partners’ was above 10 % but we could not
exclude that it was missing not at random. Lastly, self-
collected vaginal swabs have been identified as the speci-
mens of choice when screening women for Chlamydia
[18, 19]. Compared to vaginal swabs in women, use of
urine specimen in men may have led to less sensitive
detection of Chlamydia infection among men.
In Germany, the coverage of the national Chlamydia
screening programme is low, approximately 12 % of the
eligible population is reached [20]. Routine Chlamydia
testing of women and possibly men who seek HIV test-
ing at a LPHA, prioritising groups with a higher preva-
lence, provides an opportunity to detect and treat
asymptomatic infections in individuals who might not
seek Chlamydia testing otherwise. Besides, patients seek-
ing an HIV test following unprotected sex are at risk of
multiple STIs . The potential of voluntary counselling
and testing could be maximised by providing tests for
Chlamydia, and possibly other STIs, integrated in a sin-
gle service visit [21, 22].
Conclusions
LPHA offering HIV tests should consider offering rou-
tine Chlamydia testing to women under 30 years. In
addition, having multiple partners and being born
abroad were identified as independent factors associated
with Chlamydia infection, these two groups may also be
considered for routine Chlamydia testing. Being born
abroad is likely to be a proxy reflecting higher risk be-
haviours among patients born abroad seeking HIV test-
ing at LPHA. It may also reflect less access to testing
and treatment in the country of birth.
If testing of asymptomatic men visiting LPHA for an
HIV test is considered in Germany, our results suggest
offering routine Chlamydia testing to heterosexual men
under 25 years old or even under 30, depending on
where the screening threshold is set.
For MSM, young age did not seem to be a key factor
associated with urethral Chlamydia infection. We cannot
draw specific recommendations based on our study as we
estimated the prevalence of urethral Chlamydia infection
only, leaving out rectal and pharyngeal infections. Future
studies would have to include pharyngeal and rectal swabs
in order to evaluate whether routine Chlamydia testing is
warranted for MSM in this setting.
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